Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.

Sébastien GaujouxJean-Marc RegimbeauGuillaume PiessenStéphanie TruantFrantz FoissacLouise BarbierEmmanuel BucMustapha AdhamDavid FuksSophie DeguelteFabrice MuscariLaurent SulpiceJean-Christophe VaillantLilian SchwarzAntonio Sa CunhaMilena MuzzoliniBertrand DoussetAlain Sauvanetnull null

Published in: Annals of surgery (2024)

In the PREFIPS Randomized Clinical Trial including 651 patients, a total of 153 patients (23.5%) developed a grade B/C POPF with no significant difference between both groups: 24.1%: somatostatin arm and 22.9%: octreotide arm (χ 2 test, P =0.73, ITT analysis). Absence of statistically significant difference persisted after adjustment for stratification variables and in per-protocol analysis.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
randomized controlled trial
patients undergoing
clinical trial
neuroendocrine tumors